Tarsus Pharmaceuticals
Commercializes XDEMVY for Demodex blepharitis and develops additional eye-care and infectious-disease therapies.
$71.76
After-hours close−0.03 (−0.04%)
At close$71.79(−0.18%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 116.01%Insiders 3.21%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 43.02M · Float 40.39M · 93.9% free float
Institutions13F, as of Jun 30, 2026
269 holders · 49.91M shares · 43 new positions · 146 increased · 86 reduced · 36 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.86M | 8.96% | +303.5K | Aug 7, 2026 |
| Deep Track Capital, LP | 3.67M | 8.52% | +66.8K | Aug 14, 2026 |
| RTW Investments, LP | 3.36M | 7.80% | +11.0K | Aug 14, 2026 |
| Jupiter Topco LLC | 2.81M | 6.53% | +2.81Mnew | Aug 14, 2026 |
| Paradigm Biocapital Advisors LP | 2.78M | 6.45% | +213.5K | Aug 14, 2026 |
| Morgan Stanley | 1.83M | 4.25% | −117.2K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.79M | 4.17% | +32.5K | Aug 13, 2026 |
| Jennison Associates LLC | 1.66M | 3.87% | −48.5K | Aug 3, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.46% | 3.60M | 13G | May 15, 2026 ↗ |
| RTW Investments, LP | 8.10% | 3.42M | 13G | Aug 14, 2025 ↗ |
| BlackRock, Inc. | 7.40% | 3.09M | 13G | Apr 24, 2025 ↗ |
| Janus Henderson Group PLC | 5.30% | 2.24M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Bobak R. Azamian | director, officer: President/CEO and Board Chair | 881.4K | 2.05% | Jun 22, 2026 |
| William J. Phd Link | director | 106.8K | 0.25% | Jun 17, 2026 |
| Seshadri Neervannan | officer: Chief Operating Officer | 83.3K | 0.19% | Mar 24, 2026 |
| Bryan Wahl | officer: General Counsel | 64.0K | 0.15% | Mar 19, 2026 |
| Aziz Mottiwala | officer: Chief Commercial Officer | 61.5K | 0.14% | Mar 19, 2026 |
| Jeffrey S. Farrow | officer: See Remarks | 56.8K | 0.13% | Jun 17, 2026 |
| Dianne C. Whitfield | officer: Chief Human Resources Officer | 35.0K | 0.08% | Mar 19, 2026 |
| Elizabeth Yeu Lin | officer: Chief Medical Officer | 23.3K | 0.05% | Mar 19, 2026 |
| Andrew D. Goldberg | director | 19.7K | 0.05% | Jun 16, 2026 |
| Wendy L. Yarno | director | 16.7K | 0.04% | Jun 16, 2026 |
4 ten-percent owners hold 5.92M shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (2.63M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jun 17, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale · 2 lots | 10,000 | $61.55 | 847,991 |
| Jun 15, 2026 | William J. Phd Linkdirector | Sale · 2 lots | 12,500 | $62.12 | 106,786 |
| Jun 15, 2026 | Katherine Goodrichdirector | Sale | 2,954 | $62.08 | 2,233 |
| Jun 16, 2026 | Jeffrey S. Farrowofficer: See Remarks | Sale | 14,396 | $60.95 | 56,801 |
| Mar 20, 2026 | Seshadri Neervannanofficer: Chief Operating Officer | Sale | 2,989 | $66.75 | 82,791 |
| Mar 19, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale | 11,964 | $67.00 | 33,421 |
| Mar 18, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale | 11,667 | $68.71 | 45,385 |
| Mar 17, 2026 | Bobak R. Azamiandirector, officer: President/CEO and Board Chair | Sale | 10,972 | $69.42 | 57,052 |
| Mar 19, 2026 | Jeffrey S. Farrowofficer: See Remarks | Sale | 2,186 | $67.00 | 43,316 |
| Mar 18, 2026 | Jeffrey S. Farrowofficer: See Remarks | Sale | 2,133 | $68.71 | 45,502 |
CongressHouse and Senate disclosures
Not reported.